PBM (Psyence Biomedical) EBITDA Margin % : 0.00% (As of Sep. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Psyence Biomedical's EBITDA for the six months ended in Sep. 2023 was $-1.45 Mil. Psyence Biomedical's Revenue for the six months ended in Sep. 2023 was $0.00 Mil. Therefore, Psyence Biomedical's EBITDA margin for the quarter that ended in Sep. 2023 was 0.00%.

Psyence Biomedical EBITDA Margin % Historical Data

The historical data trend for Psyence Biomedical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical EBITDA Margin % Chart

Psyence Biomedical Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

EBITDA Margin %

Psyence Biomedical Semi-Annual Data
	Mar22	Sep22	Mar23	Sep23	Mar24
EBITDA Margin %	-	-	-	-	-

Competitive Comparison of Psyence Biomedical's EBITDA Margin %

For the Biotechnology subindustry, Psyence Biomedical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Psyence Biomedical's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Psyence Biomedical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Psyence Biomedical's EBITDA Margin % falls into.

Psyence Biomedical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Psyence Biomedical's EBITDA Margin % for the fiscal year that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (A: Mar. 2024 )	/	Revenue (A: Mar. 2024 )
	=	-51.106	/	0
	=	%

Psyence Biomedical's EBITDA Margin % for the quarter that ended in Sep. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-1.445	/	0
	=	%

Psyence Biomedical (NAS:PBM) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Psyence Biomedical EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Psyence Biomedical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1

Website

https://www.psyence.com

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.